Triple-negative breast cancer cells ramp up production of a key component of DNA in response to chemotherapy and that targeting this pathway could undermine their resistance to such therapies, researchers have demonstrated.
Triple-negative breast cancer cells ramp up production of a key component of DNA in response to chemotherapy and that targeting this pathway could undermine their resistance to such therapies, researchers have demonstrated.